|
1
|
Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury.
|
Kidney Int
|
2002
|
8.03
|
|
2
|
Tubular kidney injury molecule-1 in protein-overload nephropathy.
|
Am J Physiol Renal Physiol
|
2006
|
1.85
|
|
3
|
T cell, Ig domain, mucin domain-2 gene-deficient mice reveal a novel mechanism for the regulation of Th2 immune responses and airway inflammation.
|
J Immunol
|
2006
|
1.51
|
|
4
|
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
|
MAbs
|
2009
|
1.30
|
|
5
|
Growth factor induction of Cripto-1 shedding by glycosylphosphatidylinositol-phospholipase D and enhancement of endothelial cell migration.
|
J Biol Chem
|
2007
|
1.14
|
|
6
|
Requirement of glycosylphosphatidylinositol anchor of Cripto-1 for trans activity as a Nodal co-receptor.
|
J Biol Chem
|
2007
|
1.14
|
|
7
|
Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody.
|
Circulation
|
2005
|
1.11
|
|
8
|
TRAF3 controls activation of the canonical and alternative NFkappaB by the lymphotoxin beta receptor.
|
J Biol Chem
|
2010
|
1.03
|
|
9
|
Lymphotoxin β receptor mediates caspase-dependent tumor cell apoptosis in vitro and tumor suppression in vivo despite induction of NF-κB activation.
|
Carcinogenesis
|
2013
|
0.80
|
|
10
|
An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.
|
Eur J Cancer
|
2011
|
0.79
|